[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Southwest Hospital, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":318},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,72,99,123,151,177,202,224,244,265,291],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643862","deep-cervical-lymphovenous-anastomosis-for-severe-alzheimers-disease-100643862",false,"NCT07669272","Deep Cervical Lymphovenous Anastomosis for Severe Alzheimer's Disease","A Single-arm, Prospective, Self-controlled Study on Efficacy and Safety of Deep Cervical Lymphovenous Anastomosis for Neurological Function in Patients With Severe Alzheimer's Disease","DCLVA-AD","Inclusion Criteria:\n\n* Meet the 2011 NIA-AA clinical diagnostic criteria for probable Alzheimer's disease dementia and the 2018 NIA-AA research framework biomarker criteria for AD.\n* Aged 50 to 80 years (inclusive) at the time of signing informed consent.\n* Severe cognitive dysfunction: Mini-Mental State Examination (MMSE) score \\\u003C 10 points.\n* Progressive cognitive deterioration for more than 6 months reported by patient or caregiver.\n* No clinical improvement after more than 6 months of standardized drug treatment.\n* Have a designated study companion who signs informed consent, contacts the patient at least 10 hours per week and accompanies study visits.\n* Able to complete scale assessments and examinations independently or with companion assistance.\n* Voluntarily comply with study procedures, examinations and surgical treatment.\n* Patient or legal representative can sign written informed consent and abide by trial requirements.\n* Patients and families are informed of study purpose, expected efficacy and potential risks, and voluntarily provide biological samples and participate in the study.\n\nExclusion Criteria:\n\n* Severe central nervous system diseases (other than AD) that affect cognitive function or study compliance.\n* Severe\u002Funstable systemic diseases (cardiovascular, hepatic, renal, respiratory, endocrine, hematological, psychiatric diseases); life expectancy less than 24 months.\n* Surgical contraindications: severe coagulation disorders, severe -cardiopulmonary diseases (myocardial infarction\u002Frespiratory failure within recent 30 days); severe liver damage (ALT\u002FAST \\> 3 times upper limit of normal); severe renal insufficiency (eGFR \\\u003C 30ml\u002Fmin).\n* Severe primary mental disorders (other than AD) that interfere with efficacy evaluation and cognitive assessment.\n* History of intracranial hemorrhage or craniocerebral trauma within recent 1 year.\n* Alcohol or drug abuse\u002Fdependence within recent 1 year.\n* Allergy to indocyanine green, gadolinium contrast agent, 18F-florbetapir or 18F-flortaucipir.\n* Contraindications for PET examination.\n* Other conditions judged by investigators unsuitable for enrollment.","ALL","50 Years","80 Years",{"count":21,"type":22},59,"ESTIMATED","INTERVENTIONAL",[25],"NA","Alzheimer's disease (AD) is a severe neurodegenerative disease with heavy social burden. Current drugs cannot reverse disease progression. Brain glymphatic system and meningeal lymphatic dysfunction lead to impaired clearance of Aβ and Tau protein, which is an important pathogenesis of AD. Deep cervical lymphovenous anastomosis (DCLVA) can improve intracranial lymphatic drainage, promote the clearance of toxic proteins, and improve neurological function. This is a single-arm, prospective, self-controlled study to enroll 59 patients with severe AD (MMSE \\\u003C 10). All patients receive bilateral DCLVA plus routine medication. The primary endpoint is change of CDR-SB score at 12 months post-operation. Secondary endpoints include MMSE, ZBI scores and Aβ PET-CT Centiloid value. This study aims to verify the efficacy and safety of DCLVA for severe AD.",[28],"Alzheimer s Disease",[30,31,32,33],"Alzheimer Disease","Severe Dementia","Cognitive Impairment","Neurodegenerative Disease","NOT_YET_RECRUITING","2026-06-21",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":22},"2026-10-01",{"date":42,"type":22},"2029-09-30",{"name":44,"class":45},"Southwest Hospital, China","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100615561","phase-4-low-dose-tenecteplase-for-acute-ischemic-stroke-treatment-in-aging-patients-100615561","NCT07294209","Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients","Efficacy and Safety of Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients: A Prospective, Multicenter, Randomized Controlled Study","DATE-AGING","Inclusion Criteria:\n\n1. Age ≥ 70 years;\n2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS \\\u003C4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);\n3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;\n4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;\n5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;\n6. Informed consent from the patient or surrogate.\n\nExclusion Criteria:\n\n1. Imaging demonstrates multi-lobar infarction (hypodensity \\>1\u002F3 cerebral hemisphere);\n2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to\n\n   * Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)\n   * Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement\n   * Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) \\> 1.7 or Prothrombin time (PT)\\>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and\u002For PT above the upper limit of the local laboratory reference range\n   * Platelet count of below 100×10\\^9\u002F L\n   * Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)\n   * Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days\n   * Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm\n   * Neoplasm with increased haemorrhagic risk\n   * Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial\u002Fvenous malformations\n   * History of significant trauma or major surgery within the past 3 months.\n   * Any known disorder associated with a significant increased risk of bleeding\n3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fextradural hematoma, etc.);\n4. Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.22 mmol\u002FL;\n5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;\n6. Seizure at stroke onset;\n7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;\n8. Participation in other clinical trials within 3 months prior to screening;\n9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.","70 Years",{"count":57,"type":22},798,[59],"PHASE4","The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.",[62],"Acute Ischemic Stroke Patients","RECRUITING",{"date":65,"type":38},"2026-06-23",{"date":67,"type":38},"2025-12-19",{"date":69,"type":22},"2028-12-31",{"name":44,"class":45},51,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100641662","deep-cervical-lymphovenous-anastomosis-for-moderate-alzheimers-disease-100641662","NCT07658430","Deep Cervical Lymphovenous Anastomosis for Moderate Alzheimer's Disease","The Efficacy and Safety of Deep Cervical LYMphatic-Venous Anastomosis for Moderate Alzheimer's Disease: A Multicenter, Prospective, Randomized Controlled Trial","LYMVA-AD","Inclusion Criteria:\n\n* Aged 50 to 80 years old, male or female.\n* Clinically diagnosed with moderate probable Alzheimer's disease according to the NIA-AA criteria.\n* Baseline Mini-Mental State Examination (MMSE) score between 10 and 20 points.\n* Clinical cognitive decline duration of at least 6 months.\n* Stable routine anti-dementia drug treatment for more than 6 months without obvious clinical improvement.\n* Able to complete neuropsychological scale assessments, blood biomarker detection and Aβ-PET examination.\n* Have a reliable caregiver who can accompany follow-up visits and assist in completing evaluations.\n* The participant or legal surrogate voluntarily signs the written informed consent.\n\nExclusion Criteria:\n\n* Severe cardiac, hepatic, renal, respiratory or hematopoietic system dysfunction unable to tolerate surgery or anesthesia.\n* A history of intracranial surgery, severe craniocerebral trauma, stroke, brain tumor or other central nervous system diseases.\n* Other types of dementia, including vascular dementia, frontotemporal dementia, Lewy body dementia, or mixed dementia.\n* Psychiatric disorders requiring long-term medication that may affect cognitive assessment results.\n* Contraindications for PET imaging or contrast agent allergy.\n* Active infection, malignant tumor or severe wasting disease.\n* Pregnancy or breastfeeding status.\n* Participation in other interventional clinical trials within 3 months before enrollment.\n* Poor compliance or inability to complete scheduled follow-up.\n* Any other condition judged inappropriate for enrollment by the investigator.",{"count":81,"type":22},296,[25],"This is a multicenter, prospective, open-label, endpoint-blinded randomized controlled clinical study. We aim to evaluate the safety and efficacy of deep cervical lymphovenous anastomosis (LVA) combined with routine treatment for patients with moderate Alzheimer's disease, compared with routine treatment alone.\n\nA total of 296 eligible participants aged 50 to 80 years with moderate Alzheimer's disease will be enrolled and randomly divided into two groups at a 1:1 ratio. One group will receive deep cervical lymphovenous anastomosis plus standard routine treatment, while the other group will only receive standard routine treatment for Alzheimer's disease.\n\nAll participants will be followed up for 12 months after randomization. We will assess cognitive function using MMSE and CDR-SB scales, evaluate caregiver burden via ZBI scale, and detect changes in Alzheimer's disease related biomarkers including blood amyloid-beta and tau protein, as well as Aβ-PET imaging indicators. The main goal is to observe whether this surgical procedure can improve patients' neurological function and clear abnormal protein deposits in the brain, and confirm its long-term safety.\n\nThis study strictly follows ethical principles. Every participant or their legal representative will sign a written informed consent before enrollment. During the whole study period, we will closely monitor all adverse events to ensure the safety of participants.",[85],"Alzheimer's Disease",[85,87,88,89,90],"deep cervical lymphovenous anastomosis","cognitive function","randomized controlled trial","multicenter study","2026-06-13",{"date":93,"type":38},"2026-06-22",{"date":95,"type":22},"2026-07-01",{"date":97,"type":22},"2029-06-30",{"name":44,"class":45},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":122},"100629026","phase-3-efficacy-and-safety-of-intra-arterial-tenecteplase-in-acute-ischemic-stroke-patients-with-medium-vessel-occlusion-stroke-date-mevo-100629026","NCT07469293","Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)","Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO): A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Clinical Trial","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Acute isolated intracranial medium vessel occlusion (Distal middle cerebral artery M2; M3 and M4 segments of the middle cerebral artery; A1-A4 segments of the anterior cerebral artery; P1-P3 segments of the posterior cerebral artery), confirmed by imaging, with symptom onset to randomization within 24 hours;\n3. NlHSS score ≥ 5\n4. CT scan performed within 24 hours confirming that the ischemic lesion does not involve more than one-third of the territory supplied by the responsible vessel (no evidence of early large infarction)\n5. Patients with premorbid mRS 0 or 1\n6. Written informed consent obtained from the participant or a legally authorized representative\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by cranial CT or MRI;\n2. Already received intravenous thrombolysis;\n3. Planned mechanical thrombectomy;\n4. Intraoperative DSA showing vessel rupture, dissection, or contrast agent extravasation;\n5. Pregnant or breastfeeding women;\n6. Allergy to contrast agents or tenecteplase;\n7. Systolic blood pressure \\> 185 mmHg or diastolic blood pressure \\> 110 mmHg, and failure to control with oral antihypertensive medications;\n8. Genetic or acquired bleeding disorders, coagulation factor deficiencies; coagulation dysfunction, INR \\> 1.7, or use of novel oral anticoagulants within 48 hours;\n9. Blood glucose \\\u003C 2.8 mmol\u002FL (50 mg\u002FdL) or \\> 22.2 mmol\u002FL (400 mg\u002FdL), platelet count \\\u003C 100 × 10\\^9\u002FL;\n10. History of bleeding within the past month (gastrointestinal or urinary tract bleeding);\n11. Chronic hemodialysis or severe renal insufficiency (glomerular filtration rate \\\u003C 30 mL\u002Fmin or serum creatinine \\> 220 μmol\u002FL (2.5 mg\u002FdL));\n12. Severe mental disorders or inability to provide informed consent and comply with follow-up due to dementia;\n13. Concurrent malignant tumors or severe systemic diseases with an expected survival time of less than 90 days;\n14. Intracranial aneurysms or arteriovenous malformations;\n15. Participation in another clinical interventional trial within 30 days prior to randomization or currently participating in another clinical interventional trial;\n16. Occlusions in multiple vascular territories confirmed by CTA\u002FMRA;\n17. Other reasons that the investigator deems inappropriate for participation in the trial","18 Years","100 Years",{"count":109,"type":22},488,[111],"PHASE3","DATE-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of tenecteplase combined with standard medications in acute ischemic stroke patients with medium vessel occlusion stroke within 24 hours of onset.",[114],"Acute Ischemic Stroke","2026-03-18",{"date":117,"type":38},"2026-03-20",{"date":119,"type":22},"2026-03-25",{"date":69,"type":22},{"name":44,"class":45},45,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":130,"enrollmentInfo":131,"targetDuration":133,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":46},"100612268","osteomyelitis-multi-center-prospective-cohort-study-100612268","NCT07251374","Osteomyelitis Multi-center Prospective Cohort Study","Construction of a Multicenter Disease-Specific Database and Prospective Cohort for Osteomyelitis","Inclusion Criteria:\n\n1. Signed informed consent provided.\n2. Diagnosis of osteomyelitis confirmed by the site per guidelines (including definitive\u002Fsuggestive criteria).\n\nExclusion Criteria:\n\n1. Patients who, in the opinion of the investigator, are unable to comply with the entire study procedure (including postoperative management and regular follow-up) due to psychiatric, cognitive, or behavioral disorders, or other objective reasons.\n2. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.","65 Years",{"count":132,"type":22},2000,"1 Year","OBSERVATIONAL","To establish a prospective, multicenter, real-world cohort of patients with osteomyelitis, by systematically collecting and analyzing detailed treatment and follow-up data, in order to provide clinical evidence for the standardization of its treatment",[137],"Osteomyelitis of Lower Extremities",[139,140,141,142],"Osteomyelitis","Multi-center","Prospective","Disease-Specific Database","2025-11-24",{"date":145,"type":38},"2025-11-26",{"date":147,"type":22},"2025-12-10",{"date":149,"type":22},"2028-09-30",{"name":44,"class":45},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},"100576918","robotic-versus-laparoscopic-radical-surgery-for-locally-advanced-gastric-cancer-100576918","NCT06791538","Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer","A Multicenter, Prospective, Randomized Controlled Clinical Study of Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Age \\> 18 years and \\\u003C 75 years.\n2. Primary gastric lesion histologically confirmed as gastric adenocarcinoma (including papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, poorly differentiated adenocarcinoma, etc.) via endoscopic biopsy.\n3. Preoperative clinical staging as locally advanced gastric cancer (cT2-4a, N0-3, M0) according to the 8th edition of the AJCC TNM staging system.\n4. No distant metastasis on preoperative examination, and no direct invasion of the pancreas, spleen, or other adjacent organs.\n5. Preoperative ECOG performance status score of 0 or 1.\n6. Preoperative ASA (American Society of Anesthesiologists) physical status score of I-III.\n7. Consent to participate in the study and signing of the informed consent form.\n\nExclusion Criteria:\n\n1. Previous history of gastric malignancy surgery, including submucosal resection and\u002For endoscopic mucosal resection.\n2. History of upper abdominal surgery (excluding laparoscopic cholecystectomy).\n3. Preoperative imaging shows regional lymph nodes with confluent enlargement (maximum diameter ≥3cm).\n4. Patient underwent emergency surgery due to gastric tumor bleeding or perforation.\n5. History of other malignancies, or presence of other malignant tumors detected during preoperative examination.\n6. Patient has a history of malignant tumor, or other malignant tumors were found during preoperative examination\n7. ASA (American Society of Anesthesiologists) score \\>3.\n8. Severe psychiatric disorders.\n9. History of unstable angina or myocardial infarction within the past 6 months.\n10. History of cerebral infarction or cerebral hemorrhage within the past 6 months.\n11. Severe pulmonary disease with FEV1 \\\u003C 50%.\n12. Systemic corticosteroid therapy within 1 month prior to the study.\n13. Need for concurrent surgery for other diseases.\n14. Pregnant or breastfeeding women.","75 Years",{"count":160,"type":22},740,[25],"This \\[Study Type: Clinical Trial\\] aims to \\[Primary Objective: evaluate the long-term efficacy and safety of robotic gastrectomy for locally advanced gastric cancer\\] in \\[Participant Population: patients with locally advanced gastric cancer, aged \\>18 years and \\\u003C75 years\\]. The primary questions it seeks to answer are:\n\nIs the 3-year disease-free survival rate of robotic gastrectomy non-inferior to that of laparoscopic gastrectomy? Is the perioperative safety of robotic gastrectomy superior to that of laparoscopic gastrectomy? Researchers will compare \\[Intervention Groups: Robotic Gastrectomy vs. Laparoscopic Gastrectomy\\] to determine whether \\[robotic surgery offers advantages in long-term efficacy and perioperative safety\\].\n\nParticipants will:\n\nSign an informed consent form and be randomly assigned to either the robotic surgery group or the laparoscopic surgery group.\n\nUndergo the assigned surgical procedure and receive regular follow-up visits (at 30 days, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 2 years, 2.5 years, and 3 years postoperatively).\n\nComplete physical examinations, blood tests (including complete blood count, biochemical markers, and tumor markers), and imaging studies (such as abdominal CT, upper gastrointestinal endoscopy, and chest X-ray) during the follow-up period.",[164],"Gastric Cancer, Gastroesophageal Junction Cancer",[166,167],"Robotic Gastrectomy","Laparoscopic Gastrectomy","2025-06-05",{"date":170,"type":38},"2025-06-08",{"date":172,"type":38},"2025-02-01",{"date":174,"type":22},"2028-02-01",{"name":44,"class":45},2,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":19,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":201,"locationsCount":176},"100584828","efficacy-and-safety-of-neuroendoscopic-surgery-for-large-intracerebral-hemorrhage-100584828","NCT06894433","Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage","Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage: a Multicenter, Randomized, Controlled Clinical Trial","NESICH 2","Inclusion Criteria:\n\n1. Age 18-80 years old, male or female;\n2. The time between onset and admission to the first diagnostic CT is within 24 hours (for no bystanders and the time of onset is unknown, the time of the last known patient in good condition is used);\n3. Patients with supratentorial intracerebral hemorrhage (supratentorial intracerebral hemorrhage (supratentorial intracerebral hemorrhage) whose hematoma volume is ≥50ml or whose hematoma produces obvious space occupying effect and requires emergency surgery (including patients with cerebral hernia signs such as retarding or dilatation of light reflex of one pupil);\n4. Before randomization, GCS score was 5-14, NIHSS score was ≥6;\n5. mRS Before onset: 0-1 score;\n6. Randomization within 24 hours after the first diagnostic CT;\n7. The patient or family members are informed and voluntarily sign the informed consent;\n\nExclusion Criteria:\n\n1. The clinical diagnosis is caused by cerebral aneurysm, cerebrovascular malformation, moyamoya disease, brain trauma, brain tumor, massive cerebral infarction hemorrhage transformation, coagulation dysfunction, etc.;\n2. Thalamic hemorrhage, primary ventricular hemorrhage;\n3. Platelet count \\\u003C100×109\u002FL, INR \\> 1.4;\n4. Patients with advanced cerebral hernia (such as dilated bifidus and no light reflex) or unstable vital signs cannot tolerate surgery;\n5. Irreversible brain stem impairment (eye fixation, bilateral pupil dilation), GCS≤4 points;\n6. Any history of parenchyma or other intracranial subarachnoid, subdural or epidural blood and surgical history in the past 30 days;\n7. Patients with severe advanced cognitive impairment (such as AD) or who are not expected to complete the follow-up plan as required;\n8. Complicated with other serious diseases: including respiratory, circulation, digestion, urinary, endocrine, immune and blood systems;\n9. Pregnant or breastfeeding women, or those who expect to become pregnant within one year;\n10. are participating in other clinical trials (excluding: observational studies that do not involve intervention, natural history and\u002For epidemiological studies).",{"count":186,"type":22},280,[25],"This is a multicenter, randomized, controlled clinical trial comparing neuroendoscopic hematoma removal to craniotomy in the treatment of large intracerebral hemorrhage.",[190],"Intracerebral Haemorrhage",[192,193,194],"intracerebral hemorrhage","neuroendoscopic","craniotomy","2025-05-14",{"date":197,"type":38},"2025-05-18",{"date":199,"type":22},"2025-06-01",{"date":69,"type":22},{"name":44,"class":45},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":19,"enrollmentInfo":209,"targetDuration":211,"studyType":134,"phases":4,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":176},"100574559","a-prospective-cohort-study-on-the-treatment-of-locally-advanced-gastric-cancer-100574559","NCT06760858","A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer","A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer with SOX Plus Tislelizumab Combined with HIPEC","Inclusion Criteria:\n\n* Patients with newly diagnosed Her-2 negative gastric adenocarcinoma, with no prior chemotherapy, radiotherapy, or other anti-cancer treatments before the start of the clinical trial.\n* Age between 18 to 80 years old, Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.\n* Staging according to the American Joint Committee on Cancer (AJCC) 8th edition is T4aNxM0, without obstruction, perforation, or bleeding risk.\n* Good bone marrow reserve function, with the following blood criteria: white blood cell count ≥3×10\\^9\u002FL, neutrophils ≥1.5×10\\^9\u002FL, platelet count ≥100×10\\^9\u002FL, hemoglobin ≥90 g\u002FL.\n* Good organ function, with the following biochemical criteria: aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN), alanine aminotransferase (ALT) ≤2.5×ULN, serum total bilirubin ≤1.5×ULN, serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL\u002Fmin.\n* International normalized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 times ULN.\n* Urine protein \\\u003C2+, if urine protein ≥2+ then 24-hour urine protein quantification must be ≤1g.\n* Consent to provide blood and tissue samples.\n* Expected survival of more than 3 months.\n* Female subjects agree to strict contraception; male subjects with partners of childbearing potential agree to use effective contraception during the study period.\n* Voluntarily sign the informed consent form, willing and able to comply with planned visits, study treatments, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n* Participants who have been enrolled in any other drug clinical trial or have participated in any drug clinical trial within the last month.\n* Any anti-cancer treatments (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) other than the study medication (palliative external beam radiation for non-target lesions is allowed).\n* Prior use of similar chemotherapy drugs or immune checkpoint inhibitors.\n* Presence of metastatic lesions in the liver, lungs, para-aortic lymph nodes, bones, brain, adrenal glands, or pelvic and abdominal cavity.\n* Gastrointestinal perforation, obstruction, or uncontrollable diarrhea within 6 months prior to enrollment.\n* Other untreated or concurrent tumors, except for cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors. Patients with tumors that have been cured and have no evidence of disease for more than 5 years may be included. All other tumors must have been treated at least 5 years prior to enrollment.\n* Symptomatic meningiomas：\n* History of active autoimmune diseases or refractory autoimmune diseases.\n* Received corticosteroids (\\>10mg\u002Fday prednisone or equivalent dose of steroids) or other systemic immunosuppressive therapy within 14 days prior to enrollment, excluding the following treatments: steroid hormone replacement therapy (≤10mg\u002Fday); local steroid therapy; and short-term prophylactic steroid therapy for allergies or nausea and vomiting.\n* History of HIV infection or active hepatitis B\u002FC virus infection.\n* Persistent \\> Grade 2 bacterial, fungal, viral infections.\n* Active or clinically significant cardiac disease:\n* Congestive heart failure \\> New York Heart Association (NYHA) Class II;\n* Active coronary artery disease;\n* Arrhythmias requiring treatment other than beta-blockers or digoxin;\n* Unstable angina (angina symptoms at rest), new-onset angina within 3 months prior to enrollment, or unhealed wounds, ulcers, or fractures due to myocardial infarction within 6 months prior to enrollment.\n* Patients with renal failure requiring hemodialysis or peritoneal dialysis.\n* Patients requiring medication for epilepsy.\n* History of organ transplantation (including corneal transplants).\n* Allergy to the study medication or similar drugs, or suspected allergies.\n* Pregnant or breastfeeding women.\n* Major surgery, open biopsy, or significant traumatic surgery within 4 weeks prior to recruitment.\n* History of vaccination within 4 weeks prior to enrollment.\n* Patients deemed unsuitable for the study by the investigator.",{"count":210,"type":22},122,"3 Years","The clinical trial aims to assess the efficacy and safety of Tislelizumab combined with the SOX regimen and HIPEC in treating locally advanced gastric cancer. The primary and secondary objectives are as follows:\n\nTo evaluate the 3-year disease-free survival (DFS) in patients with locally advanced gastric cancer treated with systemic SOX chemotherapy plus Tislelizumab and HIPEC.\n\nTo assess the major pathological response (MPR) in these patients. Secondary objectives include safety, pathological complete response (pCR), progression-free survival (PFS), tumor regression grade (TRG), overall survival (OS), incidence of adverse reactions during treatment, postoperative adverse reactions, and treatment efficacy.\n\nParticipants will:\n\nBe willing to receive SOX plus Tislelizumab combined with HIPEC treatment (exposure group), undergo HIPEC followed by SOX and Tislelizumab to achieve stable disease (SD), partial response (PR), or complete response (CR). Patients who can undergo surgery after the second exploration will receive surgery and HIPEC treatment. If surgery is not possible, a multidisciplinary team (MDT) discussion will follow to determine the next treatment plan. Patients with progressive disease (PD) will also have an MDT discussion to determine the subsequent treatment.\n\nBe willing to receive SOX combined with HIPEC treatment (observation group), undergo HIPEC followed by SOX to achieve SD, PR, or CR. Patients who can undergo surgery after the second exploration will receive surgery and HIPEC treatment. If surgery is not possible, an MDT discussion will follow to determine the next treatment plan. Patients with PD will also have an MDT discussion to determine the subsequent treatment.\n\nTreatment details:\n\nSOX: S-1 dosage based on body surface area (BSA): \\\u003C1.25m², 40 mg bid orally, 1.25-1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg\u002Fm² IV day 1, for a total of 3 cycles.\n\nTislelizumab: 200mg IV, day 1, Q3W, for a total of 3 cycles. HIPEC: Docetaxel: 120mg, day 1, day 3.",[164],[215],"neoadjuvant chemotherapy","2025-01-06",{"date":218,"type":38},"2025-01-07",{"date":220,"type":38},"2024-12-01",{"date":222,"type":22},"2029-09-01",{"name":44,"class":45},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":19,"enrollmentInfo":230,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":241,"leadSponsor":243,"locationsCount":4},"100568511","tislelizumab-combined-with-sox-and-hyperthermic-intraperitoneal-chemotherapy-hipec-for-gastric-cancer-with-peritoneal-metastasis-a-prospective-cohort-study-100568511","NCT06682182","Tislelizumab Combined with SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: a Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with pathologically confirmed Her-2 negative gastric adenocarcinoma who have not received chemotherapy, radiotherapy, or other anti-cancer treatments before the start of the clinical trial.\n\nAge between 18 to 80 years old, Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.\n\nAmerican Joint Committee on Cancer (AJCC) 8th edition TNM staging of T1-4aNxM1 (limited to peritoneal metastasis or the presence of ascites beyond the pelvis), without obstruction, perforation, or bleeding risk.\n\nPeritoneal Cancer Index (PCI) ≤ 20. Good bone marrow reserve function, with blood routine meeting the following conditions: white blood cell count ≥ 3×10\\^9\u002FL, neutrophil count ≥ 1.5×10\\^9\u002FL, platelet count ≥ 100×10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL.\n\nGood organ function, with biochemical tests meeting the following conditions: Alanine aminotransferase (ALT) ≤ 2.5× upper limit of normal (ULN), Aspartate aminotransferase (AST) ≤ 2.5× ULN, serum total bilirubin ≤ 1.5× ULN, blood creatinine ≤ 1.5× ULN or creatinine clearance ≥ 50 mL\u002Fmin.\n\nInternational Normalized Ratio (INR) ≤ 1.5, Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 times ULN.\n\nUrine protein \\\u003C 2+, if urine protein ≥ 2+ then 24-hour urine protein quantification must show protein ≤ 1g.\n\nAgreement to provide blood\u002Ftissue samples. Expected survival of more than 3 months. Female subjects agree to strict contraception; male subjects with partners of childbearing potential agree to use effective contraception during the study period.\n\nVoluntary signing of the informed consent form, willingness and ability to comply with planned visits, study treatments, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n* Patients who are receiving other drug clinical trials or have participated in any drug clinical trials within one month before enrollment.\n\nOther anti-tumor treatments (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) except for study medication. Palliative external irradiation for non-target lesions is allowed.\n\nPrior use of similar chemotherapy drugs or immune checkpoint inhibitors. Presence of non-pelvic abdominal metastatic lesions in the liver, lungs, para-aortic lymph nodes, bones, brain, adrenal glands, etc.; patients with peritoneal metastasis in the small bowel mesentery (regions 9-12) must be excluded.\n\nGastrointestinal perforation, obstruction, or uncontrollable diarrhea within 6 months before enrollment.\n\nOther untreated or concurrent tumors, except for cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors. Patients may be enrolled if the tumor was cured and there has been no evidence of disease for more than 5 years. All other tumors must have been treated at least 5 years before enrollment.\n\nSymptomatic meningioma. History of active autoimmune disease or refractory autoimmune disease. Received corticosteroids (\\>10mg\u002Fday prednisone or equivalent dose of steroids) or other systemic immunosuppressive therapy within 14 days before enrollment, excluding the following treatments: steroid hormone replacement therapy (≤10mg\u002Fday); local steroid therapy; and short-term prophylactic steroid therapy for allergy or nausea and vomiting.\n\nHistory of HIV infection or active hepatitis B\u002FC virus infection. Persistent \\> Grade 2 bacterial, fungal, viral, or other infections.\n\nActive or clinically significant cardiac disease:\n\nCongestive heart failure \\> New York Heart Association (NYHA) Class 2; Active coronary artery disease; Arrhythmias requiring treatment other than beta-blockers or digoxin; Unstable angina (angina symptoms at rest), new-onset angina within 3 months before enrollment, or new myocardial infarction with unhealed wounds, ulcers, or fractures within 6 months before enrollment.\n\nPatients with renal failure requiring hemodialysis or peritoneal dialysis. Patients requiring medication for epilepsy. History of organ transplantation (including corneal transplants). Allergy or suspected allergy to the study medication or similar drugs. Pregnant or breastfeeding women. Major surgery, open biopsy, or major traumatic surgery within 4 weeks before recruitment (excluding biliary stents or percutaneous biliary drainage).\n\nHistory of vaccination within 4 weeks before enrollment. Patients deemed unsuitable for the study by the investigator.",{"count":231,"type":22},74,"The clinical trial aims to assess the efficacy and safety of Tislelizumab combined with the SOX regimen and HIPEC in treating gastric cancer with peritoneal metastasis. The primary and secondary objectives are as follows:\n\nPrimary objective: To evaluate the surgical conversion rate in patients with gastric cancer peritoneal metastasis treated with systemic chemotherapy plus immune checkpoint inhibitors combined with HIPEC.\n\nSecondary objectives: To assess the safety, overall survival (OS), progression-free survival, tumor regression rate, incidence of adverse reactions during treatment, postoperative adverse reaction rates, and treatment efficacy of the combination therapy.\n\nParticipants will:\n\nBe willing to receive SOX plus Tislelizumab combined with HIPEC treatment (exposure group), undergo one session of HIPEC followed by SOX plus immune checkpoint inhibitors (two cycles) to achieve stable disease (SD), partial response (PR), or complete response (CR). Patients who can undergo surgery after the second exploration will receive surgery and HIPEC treatment. If surgery is not possible, the next treatment plan will be discussed in a multidisciplinary team (MDT) meeting. Patients with progressive disease (PD) will also have their next treatment plan discussed in an MDT meeting.\n\nBe willing to receive SOX combined with HIPEC treatment (observation group), undergo one session of HIPEC followed by SOX (two cycles) to achieve SD, PR, or CR. Patients who can undergo surgery after the second exploration will receive surgery and HIPEC treatment. If surgery is not possible, the next treatment plan will be discussed in an MDT meeting. Patients with PD will also have their next treatment plan discussed in an MDT meeting.\n\nTreatment details:\n\nSOX: S-1 dosing based on body surface area (BSA): \\\u003C1.25m², 40 mg bid orally, 1.25-\\\u003C1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg\u002Fm² IV day 1, for a total of 6 cycles.\n\nTislelizumab: 200mg IV, day 1, Q3W, for a total of 6 cycles. HIPEC: Docetaxel 75mg\u002Fm² in 3500ml normal saline, at 43°C for 60 minutes.",[234],"Gastric Cancer with Peritoneal Metastasis",[236],"Tislelizumab","2024-11-07",{"date":239,"type":38},"2024-11-12",{"date":220,"type":22},{"date":242,"type":22},"2028-12-01",{"name":44,"class":45},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":251,"sex":17,"minAge":106,"maxAge":19,"enrollmentInfo":252,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":46},"100551606","biomarkers-and-imaging-markers-for-ich-100551606","NCT06462274","Biomarkers and Imaging Markers for ICH","Biomarkers and Imaging Markers Screening for Intracerebral Hemorrhage Patients","Inclusion Criteria:\n\n1. Individuals aged 18-80 years\n2. Hematoma size is more than 5 ml\n3. Evidence of a spontaneous ICH on CT scan\n4. Patient within 72 hours of ictus\n5. Glasgow Coma Scale (GCS) Score of 5-15.\n6. The history of hypertension\n\nExclusion Criteria:\n\n1. Individuals with age \\\u003C 18 years or \\> 80 years\n2. Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases.\n3. ICH secondary to tumor or trauma..\n4. If the haematological effects of any previous anticoagulants are not completely reversed.\n5. Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction.",true,{"count":253,"type":22},200,"Intracerebral hemorrhage (ICH) is a subtype of stroke associated with high mortality and disability. Basic and clinical research has contributed to our understanding of the complex pathophysiology in ICH. However, questions regarding acute diagnosis, therapeutic decisions, and prognostication of ICH remain unanswered. Molecular biomarkers and imaging markers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction and magnetic resonance imaging (MRI) scan in ischemic stroke. Therefore, the investigators aim to discovery the potential biomarkers by screening samples of blood, cerebral spinal fluid, urine, saliva, and even tissues (if available) from ICH patients, and imaging markers via serial multimodality imaging scans such as computed tomography(CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), etc. These molecular and imaging markers would assist in contributing additional information to current tools for onset warning, diagnosis, therapy monitoring, risk stratification, intervention and prognosis for ICH patients.",[256],"Intracerebral Hemorrhage","2024-06-12",{"date":259,"type":38},"2024-06-17",{"date":261,"type":4},"2014-01-01",{"date":263,"type":22},"2026-12-01",{"name":44,"class":45},{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":19,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":290},"100480736","efficacy-and-safety-of-neuroendoscopic-surgery-for-intracerebral-hemorrhage-100480736","NCT05539859","Efficacy and Safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage","Efficacy and Safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage: a Randomised, Controlled, Open-label, Blinded Endpoint Trial","NESICH","Inclusion Criteria:\n\n1. Age 18-80 years, either sex.\n2. Time from onset to the first diagnostic CT within 24 hours (for those without bystanders and with unknown onset time, use the last known time the patient was in good condition)\n3. Deep (external capsule, putamen, internal capsule, caudate nucleus) supratentorial cerebral hemorrhage with a hematoma volume ≥ 25 ml.\n4. Stability of the hematoma determined by two CT scans at different times after onset. If the hematoma enlarges 5ml then the stability of the hematoma can be detected by CT again after 6 hours until the randomization time window is closed.\n5. Pre-randomization GCS score of 5-14 and\u002For NIHSS score of ≥6.\n6. Pre-onset Modified Rankin Scale (mRS) score 0 or 1.\n7. Blood pressure recorded 6 hours prior to randomization consistently controlled at 180 mmHg or less.\n8. Randomization completed within 24 hours after the first diagnostic CT, and surgical intervention should be performed as soon as possible, no later than 6 hours after randomization, that is to say, surgery should be performed no later than 54 hours after onset.\n9. Informed and voluntarily signed informed consent by the patient or family.\n\nExclusion Criteria:\n\n1. Hemorrhage clinically diagnosed as a result of cerebral aneurysm, cerebrovascular malformation, moyamoya disease, traumatic brain injury, brain tumor, hemorrhagic transformation of a large cerebral infarct, coagulation dysfunction.\n2. Lobar hemorrhages, thalamic hemorrhages, primary ventricular hemorrhages, cerebellum hemorrhages and brain stem hemorrhages.\n3. Hematoma involving the midbrain, with dilated or unresponsive pupils.\n4. Hematoma producing life-threatening occupying effects (e.g., CT showing midline deviation of more than 1 cm, loss of cisterna ambiens) or patients who are extremely unstable and unfit for enrollment.\n5. Platelet count \\\u003C100×10\\^9\u002FL, international normalized ratio (INR) \\>1.4.\n6. Hematoma extension to ventricle and completely blocked the third or fourth ventricle.\n7. Recent history of cerebral hemorrhage (less than 1 year).\n8. Severe hepatic impairment with ALT 3 times the upper limit of normal, or AST 3 times the upper limit of normal. Severe renal insufficiency with glomerular filtration rate less than 30 ml\u002Fmin\u002F1.73 m2.\n9. Blood pressure not effectively controlled to less than 180 mmHg despite aggressive antihypertensive therapy prior to randomization.\n10. Patients with severe advanced cognitive impairment (e.g. AD) or psychiatric disorders who are unable to complete the follow-up program as required.\n11. Comorbid other serious diseases such as respiratory, circulatory, digestive, urological, endocrine, immune and hematologic disorders.\n12. Pregnant or lactating women, or those who expect to become pregnant within one year.",{"count":274,"type":22},560,[25],"To compare the efficacy and safety of neuroendoscopic hematoma removal and standard conservative treatment for patients with spontaneous supratentorial deep intracerebral hemorrhage.",[278],"Intracerebral Hemorrhage Basal Ganglia",[280,281],"Intracerebral hemorrhage","NeuroEndoscopic Surgery","2024-05-08",{"date":284,"type":38},"2024-05-10",{"date":286,"type":38},"2022-11-18",{"date":288,"type":22},"2026-09-01",{"name":44,"class":45},4,{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100513084","chinese-spondyloarthritis-inception-cohort-cespic-100513084","NCT05960864","Chinese Spondyloarthritis Inception Cohort (CESPIC)","Chinese Spondyloarthritis Inception Cohort","CESPIC","Inclusion Criteria:\n\nCrohn's disease. Acute anterior uveitis. Psoriatic arthritis with axial involvement. Reactive arthritis.\n\nExclusion Criteria:\n\nInfections, Malignancies, Major cardiovascular events, Lower intestinal perforations Other adverse events",{"count":300,"type":22},1000,"The Chinese Spondyloarthritis Inception cohort (CESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in China on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of CESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). CESPIC has been recently expanded to recruit patients with other forms of SpA \u002F conditions associated with SpA: reactive arthritis, acute anterior uveitis, Crohn's disease as well as with psoriasis \u002F axial psoriatic arthritis.",[303,304,305,306,307,308,309],"Ankylosing Spondylitis (AS) \u002F Radiographic Axial SpA (r-axSpA)","Non-radiographic Axial Spondyloarthritis (Nr-axSpA)","Axial Psoriatic Arthritis (axPsA)","Acute Anterior Uveitis (AAU)","Crohn Disease (CD)","Ulcerative Colitis (UC)","Reactive Arthritis (ReA)","2024-04-16",{"date":312,"type":38},"2024-04-17",{"date":314,"type":22},"2024-09",{"date":316,"type":22},"2030-08",{"name":44,"class":45},""]